First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial

Authors

Zixian Wang

Published

June 1, 2024

Abstract

Whether or not the addition of immunotherapy to current standard-of-care treatments can improve efficacy in proficient mismatch repair (pMMR)/microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), the predominant type of mCRC, is unclear.

Supporters

Support the authors with ResearchCoin

Journal

Med

Topics

DOI

10.1016/j.medj.2024.05.009

First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial

Authors

Zixian Wang

Published

June 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

Med

Topics

DOI

10.1016/j.medj.2024.05.009

Paper

Paper

Paper

Paper

First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial

Abstract

Supporters

Journal

Topics

DOI

First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial

Abstract

Supporters

Journal

Topics

DOI